HPV testing of samples from the AIDS Malignancy Consortium
Location(s): Kenya; Uganda; India; Brazil
The AIDS Malignancy Consortium (AMC) is a National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for AIDS-related cancers. The AMC is composed of 36 Clinical Trials Sites worldwide, five Working Groups, an Administrative Office, a Statistical Office, and an Operations and Data Management Office. Collectively, these components develop and oversee the scientific agenda, manage the groups’ portfolio of clinical trials and other scientific-based studies, and help to develop new protocols.
Four of the working groups deal with the cancers that affect HIV-positive patients—Kaposi’s Sarcoma, Lymphoma, Human Papillomavirus-related Cancers (for example, anal and cervical cancers), and Non-AIDS Defining Cancers (for example, lung cancer, head and neck cancer, liver cancer). The Laboratory Working Group oversees the Central Laboratories of the AMC and develops laboratory studies to answer important scientific questions related to cancer in HIV-positive patients. In addition, all of the groups within the AMC are working to expand the AMC globally and to conduct clinical trials for AIDS-related cancers in diverse patient populations.